Navigation Links
Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
Date:2/25/2008

ase 2 Multiple Myeloma Trial Expected by 3rd Quarter

In December 2007, HGS and Aegera Therapeutics Inc. completed a licensing and collaboration agreement providing HGS with exclusive worldwide rights (excluding Japan) to develop and commercialize HGS1029 (formerly AEG40826) and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Preclinical studies of HGS1029 in combination with the Company's TRAIL receptor antibodies demonstrated dramatic synergistic activity against a number of cancer types. HGS1029 has also shown significant anti-tumor activity alone and in combination with other agents in a broad range of cancers. HGS expects to initiate a Phase 1 clinical trial of HGS1029 in early 2008 and plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapeutic agents.

HGS has completed the enrollment and initial dosing of 105 patients in a randomized Phase 2 trial of HGS-ETR1 in combination with Velcade (bortezomib) in advanced multiple myeloma and expects to have data available in the third quarter of 2008. In December 2007, HGS initiated dosing of patients in a randomized trial of HGS-ETR1 in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

PRODUCTS IN GSK PIPELINE: 2008 A PIVOTAL YEAR

Darapladib: Presentation of Phase 2 Results Expected; 2008 Phase 3 Decision Possible

In GSK's fourth quarter and full-year 2007 results press release on February 7, 2008, GSK stated that the data from its randomized Phase 2 dose- ranging trial of darapladib in patients with coronary artery disease will be presented at the American College of Cardiology meeting in March 2008 - and that the results of GSK's randomized Phase 2/3 imaging trial of darapladib in coronary artery disease have been submitted to a major medical journal.

Darapladib was discovered by GSK based on HGS technolo
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... FOSTER CITY, Calif. , April 20, 2015 /PRNewswire/ ... with InterpretOmics Pvt. Ltd. to provide an integrated Big ... analysis of all biomarkers collected in the context of ... the needs of precise or multi-targeted drug candidates, stratified ... efficacy and disease progression free survival. ...
(Date:4/20/2015)... 2015  "Everybody is affected by cancer sooner or ... frankly brutal. We,ve got to get away from that."  ... witnessed a loved one or friend battling for their ... chemotherapy and other treatments cause the human body. It,s ... up and succumb to the disease. Dr. Dionne has ...
(Date:4/20/2015)... /CNW/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce that its wholly owned subsidiary, Portage Pharmaceuticals ... showed one of its proprietary human-derived CPP sequences and ... inhibition of NFkB signalling even if administered when the ... the blood brain barrier (BBB) in mice was studied ...
(Date:4/20/2015)... 2015   Meditope Biosciences, Inc ., a biotechnology ... today announced presentation of data demonstrating the use of ... conjugates (ADCs). The data were presented in an abstract at ... in Philadelphia . ... to the many commercial applications that may be possible ...
Breaking Biology Technology:PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the year ending 31,December ... - Setback in regulatory process for intravenous iclaprim in US, ... - Top-line results of "intravenous-to-oral" Phase II trial with oral, ... change, - Share placing, Cash ...
... Feb. 25 Cerimon Pharmaceuticals, Inc., announced ... its once-daily topical diclofenac sodium patch Phase III program. ... Phase III clinical studies with Cerimon,s diclofenac patch. ... Cerimon,s diclofenac patch compared to placebo for the treatment ...
... SAN DIEGO and MONTREAL, Feb. 25 Speid ... consultancy firm today announced that it has entered ... success rates of new drug compounds using Genizon,s ... climate in which innovative pharmaceutical and biotechnology companies ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... leaves influence the sunlight reaching inner canopy leaves by changing ... physiology of leaves within the tree canopy is not constant, ... crown. This phenomenon is expected to have important consequences for ... A new study describes how the leaves in the outer ...
... cell in your body, but the ability to view them ... experimental techniques. A team of scientists working at the National ... Irvine, recently developed a way to magnify them dramatically. Their ... this boundary between the cell and the outside world. ...
... the United States and China have discovered the first ... flowering plant whose membership includes buttercups, apple trees, maple ... in this week,s Nature, reveals a remarkably developed species, ... of the eudicots -- and perhaps flowering plants in ...
Cached Biology News:Closer look at cell membrane shows cholesterol 'keeping order' 2Fossil is best look yet at an ancestor of buttercups 2Fossil is best look yet at an ancestor of buttercups 3
... a compact instrument for gene amplification (PCR). It ... 0.5 ml tubes, or a 48-well microplate. A ... adjust height and pressure to tightly seal PCR ... excellent thermal performance, and the sample block reaches ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... Assay with SR-101 Labeled Substrates (red ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Biology Products: